Using the immune system to kill tumours

Research Opportunity
PhD, Honours, Master of Biomedical Science
Biochemistry and Molecular Biology
Bio21 Molecular Science and Biotechnology Institute
Primary Supervisor Email Number Webpage
Dr Justine Mintern 83442976 Personal web page
Co-supervisor Email Number Webpage
Professor Jose Villadangos Personal web page

Project Details

Immune checkpoint proteins include PD1, PD-L1 and PD-L2. These proteins are expressed by tumours and immune cells and prevent the develop of an effective anti-tumour immune response. Checkpoint protein inhibitors are being used in the clinic to enhance tumour immunotherapy. In this project, we aim to understand how the expression of checkpoint proteins is regulated. We will investigate when PD1, PD-L1 and PD-L2 molecules are expressed and the underlying molecular mechanisms that controls this response. We will examine expression of checkpoint proteins using a model of adoptive T cell immunotherapy for B cell lymphoma. In addition, we will undertake CRISPR/Cas9 genetic deletion to identify new molecules that are involved in the expression of PD1, PD-L1 and PD-L2 at the surface of immune cells and tumours.

Faculty Research Themes

Cancer, Infection and Immunology

School Research Themes

Cancer in Biomedicine, Cell Signalling, Molecular Mechanisms of Disease, Infection & Immunity

Research Opportunities

PhD, Honours, Master of Biomedical Science
Students who are interested in joining this project will need to consider their elegibility as well as other requirements before contacting the supervisor of this research

Graduate Research application

Honours application

Key Contact

For further information about this research, please contact a supervisor.


Biochemistry and Molecular Biology

Research Group / Unit / Centre

Mintern laboratory: Vaccine biology

Research Node

Bio21 Molecular Science and Biotechnology Institute

MDHS Research library
Explore by researcher, school, project or topic.